Radiopharmaceuticals Market to Make Great Impact in Near Future by 2031

According to the recent studies, the radiopharmaceuticals market growth will be driven by the culmination of a wide range of prominent factors, including the increase in the research and development activities aimed at effectively isolating the radioisotopes that can prove to be useful in the treatment, as well as the diagosis of of various types of disorders. Furthermore, increase in the awareness about the availability of these treatment options amongst the patients, as well as the rising demand for early and accurate diagnosis, is also expected to bolster the demand within the global radiopharmaceuticals market

The increasing popularity of nuclear medicine is creating substantial growth and expansion opportunities in the radiopharmaceuticals market. This trend can be largely attributed to the presence of 99m Tc, which is an isotope that is used in over 80 % of the diagnostic testing methods. This trend is supplementing the rising attention towards the adoption of nuclear medicine. The players and developers in the radiopharmaceuticals market are therefore focused on research and development activities that would aid them in expanding their capabilities for producing 99m Tc.

The key market segments in radiopharmaceuticals industry, based on the types of compounds include, technetium 99, gallium 68 (including dotatoc and dotatate), 11C- Choline, various derivatives of fluorine- 18, lutetium or Lu 177, zirconium 89, and 14C urea, among others. These products and solutions offered by the major contributors in the radiopharmaceuticals market are used for various indications, such as cardiology, oncology, and neurology (including neurodegenerative diseases, such as AD and PD, as well as epilepsy), among others.

Request Sample of the Report @

Asia Pacific Displays Excellent Growth Potential in Radiopharmaceuticals Market

Regionally, the radiopharmaceuticals market can be divided into various sections, including Europe, North America, and Asia Pacific, and the rest of the World. The largest radiopharmaceuticals market size can be attributed to North America. The considerable increase in the instances of new PET-CT scanner devices and equipment installations in the regional healthcare facilities, as well as the rising emand for enhanced risk assessment services for treatment of various types of cancer are propelling the growth of the North America radiopharmaceuticals market.

However, over the next decade, the regional industry of Asia Pacific shows promising potential for the development of the radiopharmaceuticals market. This trend is bolstered by the increasing instances of new product launches by leading regional players. Furthermore, the considerable growth of the local industry players, most prominently in the regional economies of China, as well as India, is also expected to aid in the expansion of the Asia Pacific radiopharmaceuticals market in the coming years.

The leading end users for the products and solutions offered by the major stakeholders in the radiopharmaceuticals market include diagnostic labs, as well as hospitals, among others. Amongst these, the largest radiopharmaceuticals market share is anticipated to be held by the hospitals segment in the coming years. This trend can be attributed to the rising number of competent and skilled medical professionals working in the radiology departments in the hospitals across the world. Furthermore, this trend is also anticipated to be bolstered by the increase in the number of promising diagnostic centers, observed over the last few years.

Make an Enquiry Before Buying @

Players in Radiopharmaceuticals Market Focusing on Product and Technology Innovation

A few of the most prominent and major manufacturers and participants functional in the radiopharmaceuticals market include Cardinal Health, Curium, Bayer AG, ordion, NTP Radioisotopes, NorthStar Medical Radioisotopes, Braun Melsungen AG, Zimmer Biomet, Otto Bock Healthcare GmbH, Lantheus Medical Imaging, Bracco Imaging, Advanced Accelerator Applications, JSC Isotope, and Smith & Nephew PLC, among others.

Featuring a consolidated commercial landscape, the radiopharmaceuticals market houses a small number of multi-national players who account for the largest industry share. The participants and manufacturers in the radiopharmaceuticals market are adopting various tactics to enhance their industry positioning, including undertaking extensive research and development initiatives to facilitate product innovation, as well as introducing new IT based services and solutions, pharmaceutical services, and launching new and innovative product technologies.

Radiopharmaceuticals Market will Generate New Growth Opportunities in Upcoming Year

The global radiopharmaceuticals market is estimated to gain a valuation of US$ 8.5 Bn by 2031, notes an assessment by Transparency Market Research (TMR). Thus, the market for radiopharmaceuticals is expected to grow at a CAGR of 7.3% during the forecast period of 2021 to 2031.

The demand for risk assessment services for cancer treatment is being increasing in the recent years across many developed nations around the world. This factor is creating revenue-generation opportunities in the radiopharmaceuticals industry, notes a TMR study on the global radiopharmaceuticals market.

The global radiopharmaceuticals market outlook provides thorough analysis of key factors impacting the growth trajectory of the market. Thus, it covers exhaustive assessment of the growth drivers, growth restraints, regional analysis, R&Ds, demand-supply ratio, competition landscape, and emerging trends in the radiopharmaceuticals market. This aside, it sheds light on the volume, share, revenues, sales, and the recent developments in the radiopharmaceuticals market, according to a study by TMR.

In the recent years, there has been increase in the patient understanding on the importance of early disease detection. Moreover, the need for precise and timely diagnosis is being increasing in the recent years. These factors are creating profitable prospects in the global radiopharmaceuticals market. Moreover, the market is being driven by a rise in the demand for molecular imaging and disease-targeted cancer therapy around the world, note analysts of a research report by TMR.

Get Sample Copy of the Report @

Rise in Number of Cancer Patients Fuels Market Growth

Monoclonal antibodies and radiolabeled peptides are being increasingly used in the treatment and identification of malignant tumors. Hence, a rise in the number of cancer patients across the globe is projected to result into profitable opportunities in the global radiopharmaceuticals market, according to analysts at TMR.

Radiopharmaceuticals are being utilized across hospitals and diagnostic centers. Owing to the availability of skilled medical practitioners in the hospital radiology departments around the world, the radiopharmaceuticals market players are is estimated gain sizable sales opportunities from the hospitals segment in the forthcoming years, notes TMR report.

Rise in Adoption of Nuclear Medicine Fuels Market Growth

Nuclear medicine is gaining impetus in the recent years owing to a rise in the availability of 99m Tc, which is an isotope utilized in 80% of diagnostic processes. Presently, approximately 25 million diagnostic procedures are being performed using 99m Tc radiopharmaceuticals every year. The accessibility to short-lived 99m Tc is one of the important factors foreseen to fuel the adoption of Technetium 99. Moreover, there has been rise in the R&Ds across the globe. This factor is boosting the growth avenues in the global radiopharmaceuticals market.

Make an Enquiry Before Buying @

Players in Radiopharmaceuticals Market Experience High Level of Competition

Some of the leading players in the radiopharmaceuticals market include Siemens Healthineers AG, Advanced Accelerator Applications (a Novartis AG Company), GE Healthcare, Jubilant Pharma Limited,  ITM Isotopen Technologien München AG, and Bayer AG.

Major companies in the radiopharmaceuticals market are utilizing different strategies such as distribution agreements, acquisitions, regional growth, and partnerships in order to stay ahead of the competition. Moreover, several enterprises are increasing investments in R&Ds in order to develop next-gen products. Such initiatives are fueling the expansion of the radiopharmaceuticals market.

North America: Leading Region in Radiopharmaceuticals Market

The global radiopharmaceuticals market is spread across many regions including Europe, North America, Asia Pacific, and Rest of the World. Among all, North America is one of the prominent regions in the market for the radiopharmaceuticals owing to many factors including the presence of many key players, surge in the installation of PET-CT scanner equipment, and rise in the utilization of disease risk assessment services for cancer treatment in the region.